Lars Rosendal: Leadership as the differentiating factor when drug development is uncertain episode artwork

EPISODE · Mar 13, 2023 · 42 MIN

Lars Rosendal: Leadership as the differentiating factor when drug development is uncertain

from Lab to Lives

Send us Fan MailToday we speak with Lars Rosendal, the VP of Global Clinical Operations at LEO Pharma. We speak about how clinical development is an innovation game - and how both governments and patients are willing to pay for innovation.Patients in many major diseases are well served. That means we need to push the innovation to bring something to market that is either much safer, or has a higher degree of efficacy. When it comes to bringing a drug through the entire clinical value chain, there is a lot of uncertainty as it is. When you are trying to aim for innovation, the uncertainty increases. What this uncertainty does to a company depends on the company size. Being in a mid-sized pharmaceutical company means that there is some room for taking risks, but also a need to balance the uncertainty with the need to ensure continued operations. We dive into what this means for trial design in different stages of clinical trials - and how some of these stages can be outsourced, whereas others should be best kept in house to build relationships with HCPs pre-drug launch. We speak about leadership in the clinical area - and the benefits of understanding the entire clinical life cycle. Drug development is both an innovation game and a horse race. Leadership is what will allow your organization to run fast - but also dare to fail in pursuit of a deep purpose. Lars recently re-organized his leadership team to structurally ensure cross-functional collaboration and drive a competitive edge. We speak about the ideas behind this restructuring, and also how it has addressed some of the most stubborn challenges of our industry. Off-mic, Lars Rosendal and Ivanna Rosendal did try to figure out if there is a family relation - but there did not appear to be one.  Guest:Lars Rosendalhttps://www.linkedin.com/in/lars-rosendal-2520a16/ [email protected] Visit Labtolives.com Do you want to try the quiz from this episode? Find the link on our LinkedIn profile: https://www.linkedin.com/company/labtolives/ Would you like to join the show as a guest or collaborator? Find out how on our website: https://www.labtolives.com/ Support the show________Reach out to Ivanna RosendalJoin the conversation on our LinkedIn pageVisit www.labtolives.com HostsAlexander Booth aka the MedTech GuyDimitri Borisevich aka the start-up GuyIvanna Rosendal aka the R&D pharma Gal

Episode metadata supplied by the publisher feed · Published Mar 13, 2023

Embed this episode

Send us Fan Mail Today we speak with Lars Rosendal, the VP of Global Clinical Operations at LEO Pharma. We speak about how clinical development is an innovation game - and how both governments and patients are willing to pay for innovation. Patients in many major diseases are well served. That means we need to push the innovation to bring something to market that is either much safer, or has a higher degree of efficacy. When it comes to bringing a drug through the entire clinical va...

Distinct summary based on available episode metadata or transcript content.

NOW PLAYING

Lars Rosendal: Leadership as the differentiating factor when drug development is uncertain

0:00 42:07

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Lab to Lives?

This episode is 42 minutes long.

When was this Lab to Lives episode published?

This episode was published on March 13, 2023.

Can I download this Lab to Lives episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!